For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.
Overview
The iShares Global Healthcare ETF (NYSEMKT:IXJ) provides broad global sector exposure, while VanEck Pharmaceutical ETF (NASDAQ:PPH) offers a more concentrated, higher-yielding approach specifically focused on pharmaceutical companies.
These funds both target the healthcare space, but with significantly different scopes of coverage. While the VanEck fund homes in on 26 pharmaceutical giants, the iShares fund casts a much wider net across 110 global stocks that include medical device makers and biotechnology firms. Choosing between them likely depends on whether investors want specific industry concentration or a more diversified sector exposure across the global market.
Details
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield as of the close of July 16 trading.
Source
Originally published at www.fool.com.